natgillin/translations-raw huggingface dataset:
Ecansya 150 mg filmovertrukne tabletter Ecansya 300 mg filmovertrukne tabletter Ecansya 500 mg filmovertrukne tabletter Capecitabin
Ecansya 150 mg film-coated tablets Ecansya 300 mg film-coated tablets Ecansya 500 mg film-coated tablets Capecitabine
Ecansya 150 mg filmovertrukne tabletter.
Ecansya 150 mg film-coated tablets
Ecansya 150 mg filmovertrukne tabletter.
NAME OF THE MEDICINAL PRODUCT
Ecansya 150 mg tabletter Capecitabin
Ecansya 150 mg tablets Capecitabine
Ecansya 300 mg filmovertrukne tabletter Capecitabin
Ecansya 300 mg film-coated tablets Capecitabine
Ecansya 300 mg filmovertrukne tabletter.
Ecansya 300 mg film-coated tablets
Ecansya 300 mg tabletter Capecitabin
Ecansya 300 mg tablets Capecitabine
Ecansya 500 mg filmovertrukne tabletter Capecitabin
Ecansya 500 mg film-coated tablets Capecitabine
Ecansya 500 mg filmovertrukne tabletter er ferskenfarvede, aflange, bikonvekse tabletter, 15,9 mm lange og 8,4 mm brede, præget med "500" på den ene side og jævne på den anden side.
Ecansya 500 mg film-coated tablets are peach colored, oblong shaped, biconvex tablets of 15.9 mm in length and 8.4 mm in width, debossed with "500" on one side and plain on other side.
Ecansya 500 mg filmovertrukne tabletter.
Ecansya 500 mg film-coated tablets
Ecansya 500 mg tabletter Capecitabin
Ecansya 500 mg tablets Capecitabine
Ecansya anvendes med eller uden andre lægemidler mod kræft, fremskreden mavekræft.
Ecansya is used with or without other anticancer medicines; advanced gastric (stomach) cancer.
Ecansya er et ”generisk lægemiddel” og et ”hybridt lægemiddel”.
Ecansya is a ‘generic’ and a ‘hybrid’ medicine.
Ecansya er ikke beregnet til børn eller unge.
Ecansya is not indicated in children and adolescents.
Ecansya er indiceret som behandling af for den adjuverende behandling af patienter, som er opereret for stadium III (Dukes stadium C) kolonkræft (se pkt.
Ecansya is indicated for the treatment of: for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer (see section 5.1).
Ecansya filmovertrukne tabletter skal synkes hele med vand senest 30 minutter efter et måltid.
Ecansya tablets should be swallowed with water within 30 minutes after a meal.
Ecansya kan inducere alvorlige hudreaktioner såsom Stevens-Johnsons syndrom og toksisk epidermal nekrolyse.
Ecansya can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Ecansya må kun ordineres af en kvalificeret læge med erfaring i brug af antineoplastiske lægemidler.
Ecansya should only be prescribed by a qualified physician experienced in the utilisation of anti- neoplastic medicinal products.
Ecansya tages to gange dagligt i doser mellem 625 og 1 250 mg pr. kvadratmeter legemsoverflade (beregnet ved anvendelse af patientens højde og vægt).
Ecansya is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient’s height and weight).
Ecansya1 capecitabin
Ecansya1 capecitabine
Ecchy-
ecchymosis
ECF: epirubicin (50 mg/ m2 som bolus på dag 1 hver 3. uge), cisplatin (60 mg/m2 som en to- timers infusion på dag 1 hver 3. uge) og 5-FU (200 mg/m2 dagligt givet som kontinuerlig infusion via et centralt venekateter).
ECF: epirubicin (50 mg/ m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
ECF: epirubicin (50 mg/ m2 som bolus på dag 1 hver 3. uge), cisplatin (60 mg/m2 som en to- timers infusion på dag 1 hver 3. uge) og 5-FU (200 mg/m2 dagligt givet som kontinuerlig infusion via et centralt venekateter).
ECF: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
Echinococcus granulosus (voksne og juvenile)
Echinococcus granulosus (mature adult and immature)
Echinococcus multilocularis (voksne og juvenile)
Echinococcus multilocularis (mature adult and immature)
Eckert & Ziegler EURO-PET Berlin GmbH, Tyskland
Eckert & Ziegler EURO-PET Berlin GmbH, Germany
Eckert & Ziegler EURO-PET Koeln/Bonn GmbH, Tyskland
Eckert & Ziegler EURO-PET Koeln/Bonn GmbH, Germany
Eckert & Ziegler EURO-PET Warszawa Sp. z o.o., Polen
Eckert & Ziegler EURO-PET Warszawa Sp. z o.o., Poland
ECOFF-værdierne for posaconazol, som adskiller vildtype-populationen fra isolater med erhvervet resistens, er blevet bestemt vha.
The ECOFF values for posaconazole, which distinguish the wild type population from isolates with acquired resistance have been determined by EUCAST methodology.
ECOFF-værdierne for posaconazol, som adskiller vildtype-populationen fra isolater med erhvervet resistens, er blevet bestemt vha.
The ECOFF values for posaconazole, which distinguish the wild type population from isolates with acquired resistance, have been determined by EUCAST methodology.
ECOG performance status (PS)= 0 ved baseline
Baseline ECOG performance status (PS) = 0
ECOG performance status (PS)= 1 ved baseline
Baseline ECOG performance status (PS) = 1
ECOG performance status (PS)= 2 ved baseline
Baseline ECOG performance status (PS) = 2
ECOG Performance Status n (%)
ECOG Performance Status, n (%)
ECOG performance status ved baseline var 0 (24%) eller 1 (76%).
Baseline ECOG performance status score was 0 (24%) or 1 (76%).
ECOG-(Eastern Cooperative Oncology Group)-performance-status var næsten ens for begge grupper, hvilket også gjaldt for antallet og typen af tidligere behandlinger.
The ECOG performance status was comparable between both groups, as was the number and type of prior therapies.
ECOG-funktionsniveau (0/1/2) ved baseline var henholdsvis 42 %/45 %/13 % i siltuximabarmen og 39 %/62 %/0 % i placeboarmen.
ECOG performance status score (0/1/2) at baseline was 42%/45%/13% in the siltuximab arm and 39%/62%/0% in the placebo arm, respectively.
ECOG-performance-score var 0 (73%) eller 1 (27%).
ECOG performance status score was 0 (73%) or 1 (27%).
ECOG-performance-score var 0 hos 61% af patienterne, og 1 hos 39% af patienterne.
ECOG performance scores were 0 for 61% of patients and 1 for 39% of patients.
ECOG-performance-score ved baseline var 0 (24%) eller 1 (76%).
Baseline ECOG performance status score was 0 (24%) or 1 (76%).
ECOG-performance-score ved baseline var 0 (31%) eller 1 (69%).
Baseline ECOG performance status was 0 (31%) or 1 (69%).
ECOG-performance-score, M-stadie, AJCC-stadie, køn, region og LDH ved baseline) kan være medvirkende til det kliniske resultat.
ECOG performance status, M stage, AJCC stage, gender, region and baseline LDH) might contribute to the clinical outcome.
ECOG-performancestatus var sammenlignelig mellem de 2 arme, og det var antallet af tidligere behandlinger også.
The ECOG performance status was comparable between both groups, as was the number of prior therapies.
ECOG-PS = 0
ECOG PS=0
ECOG-PS = 1
ECOG PS=1
ECOG=0 eller 1
ECOG=0 or 1
Econor 10 % oralt pulver (g)
Econor 10% oralpowder (g)
Econor 10 % premix og Econor 10 % oralt pulver
Econor 10% premix and Econor 10% oral powder
Econor 10% oralt pulver til svin.
Econor 10% oral powder for pigs
Econor 10% oralt pulver til svin.
Econor 10% oral powder for pigs Valnemulin
Econor 10% Premix indeholder valnemulin i form af valnemulin hydrochlorid.
Econor 10% premix contains valnemulin in the form of valnemulin hydrochloride.
Econor 10% premix til medicineret foder til svin og kaniner fås i poser med 1 kg og 25 kg.
Econor 10% premix for medicated feed for pigs and rabbits is available in 1 kg and 25 kg bags.
Econor 10% Premix til medicineret foder til svin og kaniner.
Econor 10% premix for medicated feed for pigs and rabbits
Econor 10% Premix til medicineret foder til svin og kaniner.
Econor 10% premix for medicated feed for pigs and rabbits Valnemulin
Econor 50% - 150 mg/kg foder
Econor 50% 150 mg/kg feed
Econor 50% - 50 mg/kg foder
Econor 50% 50 mg/kg feed
Econor 50% Hypromellose Talkum
Econor 50% Hypromellose Talc.
Econor 50% Premix indeholder valnemulin i form af valnemulin hydrochlorid.
Econor 50% premix contains valnemulin in the form of valnemulin hydrochloride.
Econor 50% Premix til medicineret foder til svin.
Econor 50% premix for medicated feed for pigs
Econor 50% Premix til medicineret foder til svin.
Econor 50% premix for medicated feed for pigs Valnemulin
Econor blev enten anvendt til behandling af dyr, der allerede havde fået sygdommen, eller til at forebygge udbrud af sygdommen hos svin, der var i kontakt med syge dyr, eller på landbrug, hvor sygdommen tidligere havde optrådt gentagne gange.
Econor was used either to treat animals that were already affected by a disease or to prevent the outbreak of the disease in pigs in contact with diseased animals as well as on farms with a history of repeatedly re-occurring disease.
Econor er et lægemiddel, der indeholder det aktive stof valnemulin.
Econor is a medicine that contains the active substance valnemulin.
Econor forbedrer de behandlede dyrs sundhedstilstand og vægt, men udrydder ikke nødvendigvis helt de bakterier, der har forårsaget lungeinfektionen.
Econor improves the health and weight of the treated pigs, but may not completely eliminate the bacteria that cause lung infection.
Econor forhindrede effektivt sygdommen i at udvikles med en dosis på 1-1,5 mg valnemulin/kg kropsvægt/dag (25 mg/kg foder).
Econor at a dose of 1-1.5 mg valnemulin/kg bodyweight/day (i.e.
Econor indeholder valnemulin i form af valnemulin hydrochlorid.
Econor contains valnemulin in the form of valnemulin hydrochloride.
Econor premix blandes i svine- eller kaninfoderet med en godkendt foderblander, og det medicinerede foder udleveres til landmanden til behandling af et større antal svin eller kaniner.
Econor premix is mixed into pig or rabbit food by an authorised feed mill and the resulting “medicated feeding stuff” is then distributed to the farmer to treat a large number of pigs or rabbits.
ECOPORC SHIGA injektionsvæske, suspension til svin
ECOPORC SHIGA suspension for injection for pigs
ECT [x gange øvre normalgrænse]
ECT [x-fold upper limit of normal]
Eculizumab er et humaniseret monoklonalt IgG2/4κ-antistof, der er produceret i en murin NS0-cellelinje ved rekombinant dna-teknologi.
Eculizumab is a humanised monoclonal IgG2/4 k antibody produced in NS0 cell line by recombinant DNA technology.
Eculizumab er et humaniseret monoklonalt IgG2/4κ-antistof, der er produceret i en NS0-cellelinje ved rekombinant dna-teknologi.
Eculizumab is a humanised monoclonal (IgG2/4κ) antibody produced in NS0 cell line by recombinant DNA technology.
Eculizumab er i stand til at blokere for kroppens betændelsesreaktion og dens evne til at angribe og ødelægge sine egne sårbare PNH- blodlegemer.
Eculizumab can block the body’s inflammatory response, and its ability to attack and destroy its own vulnerable PNH blood cells.
Eculizumab er udformet, så det bindes til komplementproteinet C5, der er en del af kroppens forsvarssystem, kaldet »komplementsystemet«.
Eculizumab has been designed to attach to the C5 complement protein, which is a part of the body’s defence system called the ‘complement system’.
Eculizumab kan blokere for kroppens reaktion på betændelsestilstande og dens evne til at angribe og ødelægge sine egne blodlegemer og nyreceller.
Eculizumab can block the body’s inflammatory response, and its ability to attack and destroy its own vulnerable blood and kidney cells.
eculizumab, median
eculizumab rate,
ECX: epirubicin (50 mg/ m2 som bolus på dag 1 hver 3. uge), cisplatin (60 mg/m2 som en to- timers infusion på dag 1 hver 3. uge) og capecitabin (625 mg/m2 to gange dagligt givet kontinuerligt).
ECX: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks), and capecitabine (625 mg/m2 twice daily continuously).
ECX: epirubicin (50 mg/m2 som bolus på dag 1 hver 3. uge), cisplatin (60 mg/m2 som en to- timers infusion på dag 1 hver 3. uge) og capecitabin (625 mg/m2 to gange dagligt givet kontinuerligt)
ECX: epirubicin (50 mg/m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks), and capecitabine (625 mg/m2 twice daily continuously).
ed ed
orised orised
Ed13-Piso 1- Esc.3 Quinta da Beloura 2710-693 Sintra
Industrial Area Aradippou, 7100, Larnaca, Cyprus (P.O.Box 40261, 6302 Larnaca, Cyprus)
Edad, raza, sexo
Geriatric, gender, race
Edarbi 20 mg tabletter Edarbi 40 mg tabletter Edarbi 80 mg tabletter Azilsartan medoxomil
Edarbi 20 mg tablets Edarbi 40 mg tablets Edarbi 80 mg tablets Azilsartan medoxomil
Edarbi azilsartan-medoxomil
Edarbi azilsartan medoxomil
edativa og hypnotika, anvendes til at behandle angst:
edatives and hypnotics, used to treat anxiety:
Eddikesyre Natriumacetat
Acetic acid
Eddikesyre*
Acetic acid, glacial
Eddikesyre, natrium hydroxid, polysorbat 80, sorbitol (E420) og vand til injektion.
Acetic acid glacial, sodium hydroxide, polysorbate 80, sorbitol (E420) and water for injections.
Eddikesyre, natriumacetat (vandfrit), mannitol, metacresol , vand til injektionsvæske.
Glacial acetic acid, sodium acetate (anhydrous), mannitol, metacresol , water for injections.
Eddikesyre, natriumhydroxid, sorbitol (E420), polysorbat 20 og vand til injektion.
Acetic acid, glacial, sodium hydroxide, sorbitol (E420), polysorbate 20 and water for injections.
Eddikesyre, natriumhydroxid, sorbitol (E420), polysorbat 80 og injektionsvæske.
Acetic acid, sodium hydroxide, sorbitol (E420), polysorbate 80, and water for injection.
Eddikesyre; L-histidin; Saccharose; Polysorbat 20.
Acetic acid, glacial, L-Histidine, Sucrose and Polysorbate 20.
ederende antidepressiva (medicin til behandling af depression, der kan gøre dig søvnig)
edative antidepressants (medicines used to treat depression that make you sleepy)
ederende midler (afslappende lægemidler)
edatives (medicines that relax you)
Edible hite ink indeholder: Titandioxid (E171) Propylenglycol
Edible white ink contains: Titanium dioxide (E171)
Edible hite ink indeholder: Titandioxid (E171) Propylenglycol
Edible white ink contains: Titanium dioxide (E171) Propylene glycol
Edistride 5 mg filmovertrukne tabletter er gule og runde med en diameter på 0,7 cm.
Edistride 5 mg film-coated tablets are yellow and round with diameter of 0.7 cm.
Edistride anvendes til en type diabetes kaldet "type 2-diabetes mellitus" hos voksne patienter (over
Edistride is used for a type of diabetes called “type 2 diabetes mellitus” in adult patients (aged
Edistride anvendes, hvis din diabetes ikke kan kontrolleres med andre antidiabetiske lægemidler, diæt og motion.
Edistride is used if your diabetes cannot be controlled with other medicines for diabetes, diet and exercise.
Edistride bør ikke anvendes til patienter med moderat til svært nedsat nyrefunktion (patienter med CrCl < 60 ml/min eller eGFR < 60 ml/min/1,73 m2).
Edistride is not recommended for use in patients with moderate to severe renal impairment (patients with CrCl < 60 ml/min or eGFR < 60 ml/min/1.73 m2).
Edistride bør ikke anvendes til patienter med moderat til svært nedsat nyrefunktion (patienter med kreatininclearance [CrCl] < 60 ml/min eller estimeret glomerulær filtrationshastighed [eGFR] < 60 ml/min/1,73 m2 (se pkt.
Edistride is not recommended for use in patients with moderate to severe renal impairment (patients with creatinine clearance [CrCl] < 60 ml/min or estimated glomerular filtration rate
Edistride er et lægemiddel til behandling af voksne med type 2-sukkersyge.
Edistride is a medicine used to treat adults with type 2 diabetes.
Edistride frarådes til børn og teenagere under 18 år, da det ikke er blevet undersøgt hos disse patienter.
Edistride is not recommended for children and adolescents under 18 years of age, because it has not been studied in these patients.
Edistride fås som tabletter (5 og 10 mg) og udleveres kun mod recept.
Edistride is available as tablets (5 and 10 mg) and can only be obtained with a prescription.
Edistride kan anvendes som eneste behandling til patienter, hos hvem blodsukkeret (blodets indhold af glukose) ikke er tilfredsstillende reguleret med diæt og motion alene, og som ikke tåler metformin (et andet lægemiddel mod sukkersyge).
Edistride can be used on its own in patients whose blood glucose (sugar) levels are not satisfactorily controlled with diet and exercise alone and who cannot tolerate metformin (another diabetes medicine).
Edistride kan desuden bruges som tillægsbehandling til andre lægemidler mod sukkersyge, også insulin, når disse lægemidler sammen med motion og diæt ikke regulerer sukkersygen tilstrækkeligt.
Edistride can also be used as an ‘add-on’ to other diabetes medicines, including insulin, when these medicines together with exercise and diet are not providing adequate control of the diabetes.
Edistride påvirker ikke eller kun i mindre grad arbejdssikkerheden og evnen til at færdes sikkert i trafikken.
Edistride has no or negligible influence on the ability to drive and use machines.
Edistride var mere effektivt end placebo til at nedsætte mængden af HbA1c, når det blev brugt alene eller i kombination med andre lægemidler mod sukkersyge.
Edistride was more effective than placebo at reducing the levels of HbA1c when used alone and in combination with other diabetes medicines.
Edistride, anvendt alene, blev sammenlignet med placebo (virkningsløs behandling) i to undersøgelser med 840 patienter med type 2-sukkersyge.
Edistride on its own has been compared with placebo (a dummy treatment) in two studies in 840 patients with type 2 diabetes.
Edoxaban 30 mg én gang dagligt blev anvendt til personer med en eller flere af de følgende kliniske faktorer: moderat nedsat nyrefunktion (CrCl 30 - 50 ml/min), legemsvægt ≤ 60 kg og samtidig anvendelse af specifikke P-gp-hæmmere.
Edoxaban 30 mg once daily was used for subjects with one or more of the following clinical factors: moderate renal impairment (CrCL 30 - 50 mL/min); body weight ≤ 60 kg; concomitant use of specific P-gp inhibitors.
Edoxaban 60 mg (N = 7.012)
Edoxaban 60 mg (N = 7,012)
Edoxaban 60 mg var non-inferior i forhold til warfarin for det primære endepunkt for virkning apopleksianfald eller SEE (øvre grænse for 97,5 % CI for HR var under den præspecificerede non-inferioritetsmargin på 1,38) (tabel 4).
Edoxaban 60 mg was non-inferior to warfarin for the primary efficacy endpoint of stroke or SEE (upper limit of the 97.5% CI of the HR was below the pre- specified non-inferiority margin of 1.38) (Table 4).
Edoxaban Dosis
Edoxaban Dose
Edoxaban er et substrat for efflux-transporterproteinet P-glykoprotein (P-gp), men det er ikke et substrat for optagelsestransportproteiner, såsom organisk aniontransportprotein-polypeptid OATP1B1, organisk aniontransportprotein OAT1 eller OAT3 eller organisk kationtransportprotein OCT2.
Edoxaban is a substrate for the efflux transporter P-glycoprotein (P- gp), but not a substrate for uptake transporters such as organic anion transporter polypeptide OATP1B1, organic anion transporters OAT1 or OAT3 or organic cation transporter OCT2.
EDSS-baseline, median (område)
EDSS-baseline, median (range)
EDSS-progressionen (bekræftet stigning i EDSS på mindst ét point sammenlignet med baseline) var lavere i den tidligt behandlede gruppe (Tabel 3, signifikant effekt efter 3 år, ikke signifikant effekt efter 5 år).
EDSS progression (confirmed increase in EDSS of at least one point compared to baseline) was lower in the immediate treatment group (Table 3, significant effect after 3 years, no significant effect after 5 years).
EDSS: Expanded Disability Status Scale Gd+: Gadolinium-forstærkende
EDSS: Expanded Disability Status Scale Gd+: Gadolinium-enhancing
EDURANT er ikke undersøgt til patienter med svært nedsat leverfunktion (Child-Pugh- score C).
EDURANT has not been studied in patients with severe hepatic impairment (Child-Pugh score C).
EDURANT indeholder lactose.
EDURANT contains lactose.
EDURANT må ikke anvendes i kombination med følgende lægemidler, da der kan forekomme signifikante fald i plasmakoncentrationen af rilpivirin (på grund af CYP3A-enzyminduktion eller stigning i gastrisk pH), hvilket kan medføre tab af terapeutisk effekt af EDURANT (se pkt.
EDURANT should not be co-administered with the following medicinal products, as significant decreases in rilpivirine plasma concentrations may occur (due to CYP3A enzyme induction or gastric pH increase), which may result in loss of therapeutic effect of EDURANT (see section 4.5):
EDURANT skal indtages i
EDURANT must be
EDURANTs sikkerhed og virkning hos børn < 12 år er endnu ikke klarlagt.
The safety and efficacy of EDURANT in children aged < 12 years have not yet been established.
Edvard Thomsens Vej 14 DK-2300 København S Danmark/Danmörk/Tanska info.sandoz-dk@sandoz.com Tlf: +45 6395 1000
Edvard Thomsens Vej 14 DK-2300 København S Danmörk/Danmark/Tanska info.sandoz-dk@sandoz.com Tlf: +45 6395 1000
EE AUC ↓ 0,80 (0,67 - 0,97)
EE AUC ↓ 0.80 (0.67 - 0.97)
EE Cmax ↔ 0,94 (0,79 - 1,12)
EE Cmax ↔ 0.94 (0.79 - 1.12)
een aandoening waarbij er een risico is op inwendige bloedingen (zoals een maagzweer)
a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer)
Een bijwerking die zelden voorkomt (kan bij maximaal 1 op de 1000 gebruikers voorkomen):
Uncommon side effects (may affect up to 1 in 100 people):
een bloedziekte die kan leiden tot inwendige bloedingen (bloedingen in weefsels, organen of gewrichten van uw lichaam)
a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body).
Een cross-overstudie bij 40 gezonde personen, van wie telkens 10 in ieder van de vier CYP2C19- metabolisergroepen (ultrasnel, snel, matig en slecht), evalueerde de farmacokinetische en de antiplaatjesrespons bij gebruik van 300 mg gevolgd door 75 mg/dag en bij 600 mg gevolgd door 150 mg/dag, elk voor in totaal 5 dagen (steady state).
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
Een farmacodynamische interactie tussen clopidogrel en ASA, leidend tot een verhoogd risico op bloeding, is mogelijk.
A pharmacodynamic interaction between clopidogrel and acetylsalicylic acid is possible, leading to increased risk of bleeding.
Een farmacodynamische interactie tussen clopidogrel en heparine, leidend tot een verhoogd risico op bloeding, is mogelijk.
A pharmacodynamic interaction between clopidogrel and heparin is possible, leading to increased risk of bleeding.
een geplande chirurgische ingreep (inclusief een tandheelkundige) binnen de komende zeven dagen.
a planned surgery (including dental) in the next seven days
Een passende therapie dient overwogen te worden indien zich bloedingen voordoen.
Appropriate therapy should be considered if bleedings are observed.
Een patiënt met een verminderd metabolisme bezit twee allelen met functieverlies zoals hierboven gedefinieerd.
A patient with poor metaboliser status will possess two loss-of-function alleles as defined above.
een recente chirurgische ingreep (inclusief een tandheelkundige)
a recent surgery (including dental)
een recente ernstige verwonding
a recent serious injury
een selectieve serotonine-heropnameremmer (inclusief, maar niet beperkt tot fluoxetine of fluvoxamine), geneesmiddelen gewoonlijk gebruikt om een depressie te behandelen,
a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression,
EEN SPECIALE WAARSCHUWING DAT HET GENEESMIDDEL BUITEN HET ZICHT EN BEREIK VAN KINDEREN DIENT TE WORDEN GEHOUDEN
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Eesti
Danmark
Eesti
Norge
Eesti
Suomi/Finland
Eesti
Österreich
Eesti (Estland) Generics [UK] Ltd.
Eesti (Estonia) Generics [UK] Ltd.
Eesti (Estonia)
Hrvatska
Eesti Norge
Ireland
Eesti Zoovetvaru AS Uusaru 5
Eesti Zoovetvaru AS Uusaru 5,